Top Page | English | 简体中文 | 繁體中文 | 한국어 | 日本語
  Press Releases
Tuesday, July 29, 2025
LENVIMA(R) (lenvatinib) in Combination with Pembrolizumab and Transarterial Chemoembolization (TACE) Approved in China for the Treatment of Unresectable, Non-Metastatic Hepatocellular Carcinoma
Friday, July 25, 2025
Eisai Listed for 24th Consecutive Year in FTSE4Good Index Series, an Index for Socially Responsible Investment
Wednesday, July 23, 2025
Launch of Beova(R) Tablets in Thailand for Overactive Bladder
Tuesday, July 22, 2025
Eisai To Present Four-Year Efficacy And Safety Data On Continuous Treatment With Lecanemab At The Alzheimer's Association International Conference 2025
Wednesday, July 16, 2025
Eisai Awarded "The 9th Bioindustry Award" for Drug Discovery Research for Anti- Amyloid B Monoclonal Antibody Lecanemab
Monday, July 14, 2025
"URECE" (Dotinurad) Launched in China as a treatment for Gout
Tuesday, July 8, 2025
Eisai Selected as Supplier Engagement Leader, CDP's Highest Rating in the Supplier Engagement Assessment
Monday, June 2, 2025
Eisai to Launch "Pariet S," the First Proton Pump Inhibitor RX-to-OTC in Japan
Wednesday, May 28, 2025
New Drug Approval for In-House Developed Anti-Insomnia Drug DAYVIGO (Lemborexant) in China
Wednesday, May 21, 2025
Eisai Demonstrates Commitment to Oncology Innovation at ASCO 2025

Copyright © 2025 ACN Newswire - Asia Corporate News Network
Home | About us | Services | Partners | Events | Login | Contact us | Privacy Policy | Terms of Use | RSS
US: +1 214 890 4418 | China: +86 181 2376 3721 | Hong Kong: +852 8192 4922 | Singapore: +65 6549 7068 | Tokyo: +81 3 6859 8575

Connect With us: